Sumitomo Mitsui DS Asset Management Company Ltd Acquires 133 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,951 shares of the medical research company’s stock after acquiring an additional 133 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Charles River Laboratories International were worth $1,099,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. State Street Corp raised its position in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Charles River Laboratories International by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after acquiring an additional 32,311 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 3.1 %

CRL opened at $154.93 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock’s 50 day moving average price is $178.90 and its 200-day moving average price is $192.24. Charles River Laboratories International, Inc. has a one year low of $154.01 and a one year high of $275.00. The stock has a market cap of $7.92 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 6.47 and a beta of 1.37.

Wall Street Analyst Weigh In

CRL has been the subject of several research reports. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).